Effect of tNGS on CAP Patients With Initial Treatment Failure
Key facts
- Who runs it
- Capital Medical University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 524 people, planned
- Started
- 10 Apr 2026
- Expected to end
- 28 Feb 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Targeted next-generation sequencing
- Conventional microbiological testing
- Follow-up at Day 30
- Record updated
- 16 March 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Adults (age ≥ 18 years)
- Diagnosed of community-acquired pneumonia
- Initial treatment failure
Who cannot take part
- Nasopharyngeal carcinoma currently receiving radiotherapy
- tNGS or mNGS already performed on respiratory samples during the current illness
- Suspected lung abscess or empyema
- Cerebral infarction within the past three months
- Dysphagia
- Tracheostomy
- Long-term bedridden patients (ADL score ≤ 60)
- Pathogens identified within the past 7 days that adequately explain the current clinical presentation
- Bronchiectasis with large amounts of sputum and documented bacterial detection within the past six months
- Inability to obtain eligible respiratory samples
- CURB-65 score ≤ 1
- Expected discharge or death within 48 hours
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a multicenter, randomized controlled trial designed to evaluate the impact of tNGS in patients with community-acquired pneumonia who experience initial treatment failure.
The 2 groups in the trial
- tNGS groupTreatment being tested
Lower respiratory tract samples collected (BALF, sputum); undergo targeted next-generation sequencing in addition to conventional microbiological testing; follow-up by telephone on day 30 (D30).
Treatment: Targeted next-generation sequencing, Conventional microbiological testing, and Follow-up at Day 30
- Control groupExisting treatment, for comparison
Lower respiratory tract samples collected (BALF, sputum); undergo conventional microbiological testing; follow-up by telephone on day 30 (D30).
Treatment: Conventional microbiological testing and Follow-up at Day 30
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Impact of Targeted Next-generation Sequencing on Hospitalized Patients With Community-acquired Pneumonia and Initial Treatment Failure
- Record updated
- 16 March 2026